It was reported that on (b)(6) 2021, the 4.5x80 mm supera self expanding stent was implanted in the superficial femoral artery (sfa) with heavy calcification and moderate tortuosity.During a 12 month follow up, it was reported that the patient had expired.The reason and date of death are not known.It is not known if the supera caused or contributed to the death.No additional information was provided.
|
The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of death is listed in the supera peripheral stent system instructions for use as a potential adverse effect of peripheral percutaneous intervention.A conclusive cause for the reported patient effect, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.Outcomes attributed to adverse event: date of event/death is estimated as (b)(6) 2022.
|